Leveraging AIM’s BioAvatar technology to tackle previously-unknown effects of immune protein ligands in tumors
Although immune checkpoint protein PD-1 activation is known to participate in tumor development and to inhibit adoptive T cell therapy effects, the expression of its ligand PD-L1 during oncogenesis progression is not well understood. A group of scientists studied the...
New application note with AIM Biotech and Nikon: Evaluating CAR-T cell dynamics in a 3D tumor microenvironment using confocal imaging
AIM Biotech and Nikon Instruments have produced a new application note demonstrating one way to more easily study the immune effects of Chimeric Antigen Receptor T (CAR-T) by combining AIM’s three-dimensional idenTx cell assays with confocal imaging technology....
Simplify and isolate: A case study on how idenTx streamlines preclinical research
For today’s post in our immune checkpoint series, we’ll discuss work published in Cell in 2018 by Sade-Feldman et al., and how they leveraged the economy of cost from AIM’s idenTx organ-on-a-chip assays to turn what would have been a six-variable animal study into a...
Step-by-step: Data and insights from a human cancer-on-a-chip model
Having a human cell-based model that mimics the in vivo tumor microenvironment and cell-to-cell interactions is invaluable for studying new cancer therapies. In our last post, we talked about growing spheroids using our idenTx family of 3D tissue culture chips and...